- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04320472
Acute Encephalopathy in Critically Ill Patients With COVID-19 (NeuroCOVID19)
Outcomes in Patients With Acute Encephalopathy and SARS-Cov-2 Infection
Infection with SARS-CoV-2 or severe acute respiratory syndrome coronarvirus type 2 was highlighted in December 2019 in the city of Wuhan in China, responsible for an pandemic evolution since March 11, 2020. The infection affects all ages of life, although affecting children in a very small proportion of cases. The typical presentation of the disease combines fever (98%), cough (76%), myalgia and asthenia (18%) as well as leukopenia (25%) and lymphopenia (63%). Upper airway involvement rare.
The main clinical presentation requiring hospitalization of infected patients is that of atypical pneumonia which may require critical care management (27%), and progress to an acute respiratory distress syndrome (67%) involving life-threatening conditions in almost 25% of patients diagnosed with SARS-CoV-2 infection. Other organ damage have been reported, mainly concerning kidney damage (29%) which may require renal replacement therapy in approximately 17% of patients.
Neurological damage has been very rarely studied, yet reported in 36% of cases in a study including patients of varying severity.
Finally, the mortality associated with this emerging virus is high in patients for whom critical care management is necessary, reported in 62% of patients.
We therefore propose a prospective observational study which aim at reporting the prevalence of acute encephalopathy at initial management in Critical/Intensive care or Neurocritical care , to report its morbidity and mortality and to identify prognostic factors.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All patients with SARS-CoV-2 infection and acute encephalopathy at presentation will be prospectively included in the NEURO-COVD-19 study. This study will collect demographic data, clinical examen at prehospital/emergency room and ICU admission (including neurological signs), and all ancillary exams performed to identify a cause of neurological impairment. Outcome will be evaluated using the Glasgow Outcome Scale score at ICU and hospital discharge, and day-90 after ICU admission.
Acute encephalopathy will be defined as recently stated :
"1. The term acute encephalopathy refers to a rapidly developing (over less than 4 weeks, but usually within hours to a few days) pathobiological process in the brain. This is a preferred term 2. Acute encephalopathy can lead to a clinical presentation of subsyndromal delirium, delirium, or in case of a severely decreased level of consciousness, coma; all representing a change from baseline cognitive status 3. The term delirium refers to a clinical state characterized by a combination of features defined by diagnostic systems such as the DSM-5. Delirium according to the DSM-5 is defined if criterium A-E are fulfilled: A. Disturbance in attention (i.e., reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced orientation to the environment). B. The disturbance develops over a short period of time (usually hours to a few days) represents a change from baseline attention and awareness, and tends to fluctuate in severity during the course of the day. C. An additional disturbance in cognition (e.g., memory deficit, disorientation, language, visuospatial ability, or perception). D. The disturbances in criteria A and C are not explained by another pre-existing, established, or evolving neurocognitive disorder, and do not occur in the context of a severely reduced level of arousal, such as coma. E. There is evidence from the history, physical examination, or laboratory findings that the disturbance is a direct physiologic consequence of another medical condition, substance intoxication or withdrawal (i.e. because of a drug of abuse medication), or exposure to a toxin, or is because of multiple etiologies. " (Slooter, A.J.C., Otte, W.M., Devlin, J.W. et al. Updated nomenclature of delirium and acute encephalopathy: statement of ten Societies. Intensive Care Med (2020). https://doi.org/10.1007/s00134-019-05907-4)
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
São Paulo, Brazil
- Universidade Federal de São Paulo
-
-
-
-
-
Cali, Colombia
- Fundación Valle del Lili, University Hospital
-
-
-
-
-
Cairo, Egypt
- Cairo University Hospitals
-
-
-
-
-
Argenteuil, France
- Centre Hospitalier d'Argenteuil
-
Beauvais, France
- Centre Hospitalier De Beauvais
-
Boulogne, France
- Centre Hospitalier Universitaire Ambroise Paré
-
Bourg-en-Bresse, France
- Centre Hospitalier de Bourg en Bresse
-
Brest, France
- Centre hospitalier régional universitaire de Brest
-
Brive-la-Gaillarde, France
- Centre Hospitalier de Brives
-
Clichy, France
- Centre Hospitalier Universitaire Beaujon
-
Colombes, France
- Centre Hospitalier Universitaire Louis Mourier
-
Créteil, France
- Centre Hospitalier Universitaire Henri Mondor
-
Dieppe, France
- Centre Hospitalier de Dieppe
-
Dijon, France
- Centre Hospitalier Universitaire de Dijon
-
Etampes, France
- Centre Hospitalier d'Etampes
-
Jossigny, France
- Grand Hôpital de l'Est Francilien - Site de Marne-la-Vallée
-
La Roche-sur-Yon, France
- Centre Hospitalier de la Roche-sur-Yon
-
La Rochelle, France
- Centre Hospitalier de La Rochelle
-
Le Chesnay, France, 78150
- Centre Hospitalier de Versailles
-
Lille, France
- Centre Hospitalier Universitaire de Lille
-
Lyon, France
- Centre Hospitalier Universitaire Hôpital Edouard Herriot
-
Massy, France
- Hôpital privé Jacques Cartier
-
Melun, France
- Groupe Hospitalier Sud Ile-de-France
-
Orléans, France
- Centre Hospitalier Regional D'Orleans
-
Paris, France
- Hôpital Fondation Adolphe de Rothschild
-
Paris, France
- Groupe Hospitalier Paris Saint-Joseph
-
Paris, France
- Centre Hospitalier Universitaire Cochin
-
Quincy-sous-Sénart, France
- Hôpital Privé Claude Galien
-
Rennes, France
- Centre hospitalier universitaire de Rennes
-
Roanne, France
- Centre Hospitalier de Roanne
-
Suresnes, France
- Hôpital FOCH
-
Toulon, France
- Centre Hospitalier de Toulon
-
Toulouse, France
- Centre Hospitalier Universitaire de Toulouse
-
Tours, France
- Centre Hospitalier Universitaire de Tours
-
Villejuif, France
- Gustave-Roussy
-
-
-
-
-
Guanajuato, Mexico
- Hospital Regional de Alta Especialidad del Bajio
-
-
-
-
-
Valencia, Spain
- Hospital Clinic Universitari
-
-
-
-
Florida
-
Miami, Florida, United States, 33136
- Jackson Memorial Health System; University of Miami, Miller School of Medicine
-
-
Georgia
-
Atlanta, Georgia, United States, 30312
- Wellstar Atlanta Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Critical/Intensive care or Neurocritical care admission
- Admission for/with acute encephalopathy defined as a rapidly developing (over less than 4 weeks, but usually within hours to a few days) pathobiological process in the brain; including delirium or subsyndromal (DSM V definition) or coma (Glasgow coma scale score < 9)
- SARS-COV-2 infection (respiratory or other PCR specimen)
- Age ≥ 18 years
Exclusion Criteria:
- Opposition to study participation from the patient itself or patient surrogate
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Follow up
Follow up of all included patients up to 3 months after enrollement
|
Follow up up to day 90 (Glasgow outcome scale, Glasgow outcome scale extended, functionnal impairments : Barthel index, Disability Rating Scale)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
prevalence
Time Frame: at Critical/Intensive care or Neurocritical care admission
|
ratio of patients with acute encephalopathy among the total of patients with SARS-Cov-2 infection at Critical/Intensive care or Neurocritical care admission
|
at Critical/Intensive care or Neurocritical care admission
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Favorable outcome
Time Frame: 3 months
|
A favorable outcome is defined by a Glasgow Outcome Scale (GOS) of 5.
The Glasgow Outcome Scale (GOS) will be determined patients charts review, phone call, and/or general practitioner interview conducted by an independent assessor.
The GOS score : [1: Death, 2: Persistent vegetative state, 3: Severe disability, 4: Moderate disability, 5 : Low disability]
|
3 months
|
Favorable outcome
Time Frame: 3 months
|
A favorable outcome is defined by a Glasgow Outcome Scale Extended (GOSe) >= 5.
The Glasgow Outcome Scale Extended (GOSe) will be determined patients charts review, phone call, and/or general practitioner interview conducted by an independent assessor.
The GOSe score : [1: Death, 2: Persistent vegetative state, 3: Severe disability Lower, 4: Severe disability Upper, 5: Moderate disability Lower, 6: Moderate disability Upper, 7 : Good recovery lower, 8 : Good recovery Upper]
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stephane LEGRIEL, MD, PhD, Ictal Group
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Central Nervous System Diseases
- Nervous System Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- COVID-19
- Brain Diseases
- Critical Illness
Other Study ID Numbers
- Neuro-Covid-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
Clinical Trials on Follow up
-
Istanbul University - Cerrahpasa (IUC)CompletedInfertility | Psychological Distress | Infertility, Female | Depression, Anxiety | Nurse's RoleTurkey
-
M.D. Anderson Cancer CenterRecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Connolly Hospital BlanchardstownCompletedGeneral Surgery | Outpatients | Virtual Clinic | Text MessagingIreland
-
Sport Injury Prevention Research CentreGeneral Electric; National Basketball AssociationCompletedTendinopathy | Sports Injuries in Children | Injury, Knee | Injury, AnkleCanada
-
Centre Hospitalier Universitaire, AmiensRecruitingQuality of Life | Pain | Lumbar Spine SurgeryFrance
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and Development; Trialbureau... and other collaboratorsRecruitingAdolescent Idiopathic ScoliosisNetherlands
-
University of IcelandMemorial Sloan Kettering Cancer Center; Landspitali University Hospital; deCODE... and other collaboratorsActive, not recruitingMonoclonal Gammopathy of Undetermined SignificanceIceland
-
Rennes University HospitalUnknown
-
Centre Hospitalier Universitaire DijonRecruitingMyocardial Infarction | Cerebrovascular AccidentsFrance
-
Rennes University HospitalMinistry of Health, FranceCompletedTelemedicine | Defibrillators, ImplantableFrance